Medicare AdvantagePrior AuthMedium impact
Lynparza (olaparib) (Revised)
Humana·Oncology, Hematology·Medicare Advantage
Effective date
Jan 1, 2026
We identified it
Jun 24, 2026
Summary
Humana Medicare Advantage has updated prior authorization criteria for Lynparza (olaparib), an oncology medication used to treat breast cancer, ovarian cancer, prostate cancer, and pancreatic adenocarcinoma. The policy now requires specific BRCA mutation testing, response to prior treatments, and excludes patients who have progressed on PARP inhibitor therapy.
Action Required
Before January 1, 2026: Clinical staff must verify patients meet updated prior authorization criteria for Lynparza including BRCA mutation testing documentation, response to prior chemotherapy, and exclusion screening for previous PARP inhibitor therapy progression. Update prior authorization request templates to include required genetic testing results and treatment history documentation. Claims will be denied without proper authorization.